253 related articles for article (PubMed ID: 36396025)
1. Hepatitis D virus: Improving virological knowledge to develop new treatments.
Khalfi P; Kennedy PT; Majzoub K; Asselah T
Antiviral Res; 2023 Jan; 209():105461. PubMed ID: 36396025
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis D: A Review.
Negro F; Lok AS
JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
[TBL] [Abstract][Full Text] [Related]
3. Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus.
Asselah T
J Viral Hepat; 2023 Apr; 30 Suppl 1():33-38. PubMed ID: 36529713
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatitis delta and HIV infection.
Soriano V; de Mendoza C; Treviño A; Ramos-Rincón JM; Moreno-Torres V; Corral O; Barreiro P
Liver Int; 2023 Aug; 43 Suppl 1():108-115. PubMed ID: 35748639
[TBL] [Abstract][Full Text] [Related]
5. Future treatments for hepatitis delta virus infection.
Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
[TBL] [Abstract][Full Text] [Related]
6. New therapies for hepatitis delta virus infection.
Loureiro D; Castelnau C; Tout I; Boyer N; Narguet S; Menasria Benazzouz S; Louis Z; Pons-Kerjean N; Giuly N; Marcellin P; Mansouri A; Asselah T
Liver Int; 2021 Jun; 41 Suppl 1():30-37. PubMed ID: 34155804
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis Delta Infection: A Clinical Review.
Pearlman B
Semin Liver Dis; 2023 Aug; 43(3):293-304. PubMed ID: 37473778
[TBL] [Abstract][Full Text] [Related]
8. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
Lütgehetmann M; Mancke LV; Volz T; Helbig M; Allweiss L; Bornscheuer T; Pollok JM; Lohse AW; Petersen J; Urban S; Dandri M
Hepatology; 2012 Mar; 55(3):685-94. PubMed ID: 22031488
[TBL] [Abstract][Full Text] [Related]
9. Bulevirtide and emerging drugs for the treatment of hepatitis D.
Xu HY; Yang JO; Chen PH; Han SB
Expert Opin Biol Ther; 2023; 23(12):1245-1253. PubMed ID: 37853604
[TBL] [Abstract][Full Text] [Related]
10. Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity.
Roca Suarez AA; Batbold E; Bartosch B; Dashdorj N; Testoni B; Zoulim F
Liver Int; 2023 Aug; 43 Suppl 1():87-95. PubMed ID: 37017060
[TBL] [Abstract][Full Text] [Related]
11. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
Asselah T; Loureiro D; Le Gal F; Narguet S; Brichler S; Bouton V; Abazid M; Boyer N; Giuly N; Gerber A; Tout I; Maylin S; Bed CM; Marcellin P; Castelnau C; Gordien E; Mansouri A
Liver Int; 2021 Jul; 41(7):1509-1517. PubMed ID: 33999515
[TBL] [Abstract][Full Text] [Related]
12. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Scholtes C; Facchetti F; Loglio A; Monico S; Fraquelli M; Costantino A; Ceriotti F; Zoulim F; Lampertico P
J Hepatol; 2022 Dec; 77(6):1525-1531. PubMed ID: 35973578
[TBL] [Abstract][Full Text] [Related]
13. [Delta hepatitis: Epidemiology, diagnostic, natural history and treatment].
Loureiro D; Castelnau C; Bed CM; Asselah T
Rev Med Interne; 2022 Mar; 43(3):160-169. PubMed ID: 34799189
[TBL] [Abstract][Full Text] [Related]
14. [Hepatitis D virus: viral cycle and new therapeutic approaches].
Turon-Lagot V; Saviano A; Schuster C; Verrier ÉR
Virologie (Montrouge); 2019 Jun; 23(3):149-159. PubMed ID: 31210131
[TBL] [Abstract][Full Text] [Related]
15. Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.
Sandmann L; Deterding K; Bremer B; Port K; Cornberg M; Wedemeyer H; Maasoumy B
J Viral Hepat; 2023 Apr; 30(4):283-286. PubMed ID: 36648369
[TBL] [Abstract][Full Text] [Related]
16. Bulevirtide for HBV and HDV infections.
Yardeni D; Koh C
Drugs Today (Barc); 2021 Jul; 57(7):433-448. PubMed ID: 34268531
[TBL] [Abstract][Full Text] [Related]
17. What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options.
Asselah T
Clin Liver Dis; 2023 Nov; 27(4):985-995. PubMed ID: 37778781
[TBL] [Abstract][Full Text] [Related]
18. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A
Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446
[TBL] [Abstract][Full Text] [Related]
19. Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.
Wang W; Lempp FA; Schlund F; Walter L; Decker CC; Zhang Z; Ni Y; Urban S
J Hepatol; 2021 Aug; 75(2):311-323. PubMed ID: 33845061
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis delta virus: From infection to new therapeutic strategies.
Niro GA; Ferro A; Cicerchia F; Brascugli I; Durazzo M
World J Gastroenterol; 2021 Jun; 27(24):3530-3542. PubMed ID: 34239267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
